What is Quizartinib?

Quizartinib (Quizartinib), trade name Vanflyta, is an oral small molecule receptor tyrosine kinase inhibitor mainly used to treat acute myeloid leukemia (AML). This drug is specifically targeted at FLT3-ITD mutation-positive AML patients. By inhibiting FLT3 kinase activity, blocking receptor autophosphorylation, and then inhibiting downstream FLT3 receptor signaling, it inhibits FLT3-ITD-dependent cell proliferation, slows down disease progression, and improves patient survival rate.

FLT3 mutation is one of the most common genetic abnormalities in acute myeloid leukemia, and approximately 25% of AML patients carry FLT3-ITD mutations. The presence of this mutation is closely related to poor prognosis, often leading to high recurrence rates and short survival in patients. Therefore, patients with FLT3-ITD-positive AML are in urgent need of effective treatments. The emergence of quizartinib provides a new treatment option for these patients.

Quizatinib's clinical trial data show that the drug shows good efficacy in the treatment ofFLT3-ITD-positive AML patients. For example, a randomized, double-blind, placebo-controlled trial called QuANTUM-First enrolled 539 patients with newly diagnosed FLT3-ITD-positive AML. The results showed that patients in the quizartinib group had a statistically significant improvement in overall survival, and the complete response rate and duration of response were also better than those in the placebo group.

The recommended dose and administration of quizartinib are based on the patient's specific condition. The usually recommended starting dose is 60 mg once daily, but doctors will adjust the dose based on the patient's weight, condition and tolerance. During use, patients need to closely monitor their condition and promptly report any symptoms of discomfort to their doctor. In addition, due to the possible effects of Quizartinib on ECG, patients need regular ECG monitoring.

It is worth noting that quizartinib is not suitable for allAML patients. It is mainly used to treat adult patients who are FLT3-ITD positive and have received at least one treatment with poor response. Before use, doctors need to test the patient's FLT3 gene mutation status to ensure whether the patient is suitable for treatment with the drug.

Although quizartinib has shown good efficacy in the treatment of patients with FLT3-ITD-positive AML, it is also accompanied by certain adverse reactions. Common adverse reactions include nausea, vomiting, diarrhea, fatigue, headache, etc. In addition, some patients may experience electrocardiographic abnormalities such as QT interval prolongation. Therefore, when using quizartinib, patients need to be closely monitored for adverse reactions and take appropriate management measures to ensure patient safety.

In general, quizartinib is a targeted therapy for patients with FLT3-ITD-positive AML. It blocks the proliferation and survival signaling pathways of abnormal leukemia cells by inhibiting FLT3 kinase activity, thereby inhibiting the growth and spread of tumors. Although it is accompanied by certain adverse reactions and usage restrictions, it is undoubtedly an important treatment option for patients with FLT3-ITD-positive AML.

xa0

Reference materials:https://www.drugs.com/vanflyta.html